PANLAR

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Total, KCR, European Renal Association, Autoimmune hepatitis, Week, Cohort, European Alliance of Associations for Rheumatology, Pharmacokinetics, AIH, G&A, ERA, Congress, CRR, Patient, NKF, National Kidney Foundation, ALT, KZR, EULAR, AST, Safety, European Alliance, UPCR, PANLAR, Pharmaceutical industry, Rare-earth element, Vaccine, Rheumatology, LN

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
  • The complete MISSION Phase 1b/2 results were presented as an oral presentation at the LUPUS & KCR 2023 meeting, which took place May 17-20, 2023 in Seoul, Korea.
  • Research and development expenses for the second quarter of 2023 increased by $9.7 million to $21.0 million compared to $11.3 million in the second quarter of 2022.
  • General and administrative (G&A) expenses for the second quarter of 2023 increased by $0.8 million to $5.8 million compared to $5.0 million in the second quarter of 2022.

Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Abstract, Total, KCR, Therapy, Autoimmune hepatitis, European Renal Association, Week, European Alliance of Associations for Rheumatology, Pharmacokinetics, AIH, G&A, ERA, Congress, CRR, Patient, NKF, Lupus nephritis, Drug discovery, National Kidney Foundation, ALT, KZR, Kezar Pavilion, EULAR, Research, AST, Safety, European Alliance, UPCR, PANLAR, Pharmaceutical industry, Rare-earth element, Rheumatology, LN

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.
  • Kezar plans to initiate the dose expansion study in the second half of 2023, with topline data expected starting mid-2024.
  • Kezar plans to report safety and dose escalation data from this trial in the second half of 2023.
  • Research and development expenses for the first quarter of 2023 increased by $7.4 million to $18.3 million compared to $10.9 million in the first quarter of 2022.

CreakyJoints Español Discovers that Spanish-Language Rheumatoid Arthritis Misinformation is Viewed Twice as Often in Online Videos Compared to Verified Facts

Retrieved on: 
Thursday, August 12, 2021
Other Consumer, Women, Seniors, Men, Hispanic, Other Health, Health, Consumer, General Health, Diet, MS, Rheumatoid arthritis, Vitamin, Arthritis, Caregiver, News, Medical Affairs Bureau, YouTube, Hispanic and Latino Americans, Injury, Conditional sentence, Disease, MD, Patient, Centers for Disease Control and Prevention, Phrase, Instagram, Fear, Conference, Human voice, Social media, Emotion, Diagnosis, WhatsApp, Physician, RA, Education, Center, PANLAR, Prevalence, Medical device, Public relations

Unfortunately, the general health information available for the Hispanic community online is often times dangerous misinformation leading to low levels of diagnosis and a growing knowledge gap .

Key Points: 
  • Unfortunately, the general health information available for the Hispanic community online is often times dangerous misinformation leading to low levels of diagnosis and a growing knowledge gap .
  • The most viewed misinformation videos claim to have novel cures for RA in the title.
  • It was also noted that all top three factual videos presented RA in a complex way, using more technical and high-level language than the misinformation videos.
  • CreakyJoints Espaol is a digital community for millions of arthritis patients and caregivers worldwide who seek education, support, advocacy, and patient-centered research.